m+Medelevator.RU
← Поиск публикаций
World journal of surgical oncology · 2025

Postoperative bladder training in patients with mid-low rectal cancer facilitates early removal of the urinary catheter: a prospective, randomized, open-label, blinded-endpoint trial.

Equivalence TrialСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Yongsen, Chen Yuezhi, Zhang Xin, Zhang Jizhun

Аннотация

BACKGROUND: To evaluate whether intermittent catheterization for bladder training can reduce urinary catheterization duration in patients undergoing mid-low rectal cancer surgery.

METHODS: Stratified by gender, 330 patients were divided into a 5-day catheterization control group, and experimental groups A (3-day bladder training) and B (5-day bladder training), with 110 patients each.

RESULTS: Two-way ANOVA found that gender affected recatheterization, Pdet@Qmax, Qmax, BOOI and three-day total urine volume. No difference between groups A and B. Patients in experimental group A had a shorter time to first void (P = 0.030) and lower three-day average residual urine volume (P = 0.011) than the control group, and patients in experimental group B had a larger urine volume (P = 0.043) and lower first residual urine volume (P = 0.001). Bladder training reduced recatheterization in males. The nomogram constructed based on the logistic regression model better predicted the risk of urinary tract infection (AUC = 0.669) and recatheterization (AUC = 0.731). These two models may help provide new tools for the postoperative care of patients with mid-low rectal cancer.

CONCLUSIONS: Three-day catheter removal after bladder training is non-inferior to five-day removal. Bladder training is effective in reducing the chances of recatheterization in patients with mid-low rectal cancer.

TRIAL REGISTRATION: This study was registered with the China Clinical Trials Registry at 22th March, 2018 (No. ChiCTR1800015313, https://www.chictr.org.cn/showproj.html?proj=26123 ).

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты